Cardiff Oncology Inc (CRDF)

NASDAQ
1.520
+0.060(+4.11%)
After Hours
1.520
0.000(0.00%)
- Real-time Data
  • Volume:
    106,653
  • Day's Range:
    1.480 - 1.550
  • 52 wk Range:
    1.130 - 3.410

CRDF Comments

What is your sentiment on Cardiff Oncology?
or
Market is currently closed. Voting is open during market hours.

All Comments

(31)
  • I really like this failure, I bought it for $ 3, I hope it will fly into the stratosphere soon!!!
    0
    • cardiff 100$
      0
      • about to pop
        0
        • 11.20 soon
          0
          • To the moon 🚀
            0
            • Wow its going to gain sooner
              0
              • Zman Any tips for bull?
                0
              • https://seekingalpha.com/article/4400581-first-look-cardiff-oncology
                0
                • In green! Very important step in the right direction. Price is at +11.45% from yesterdays low!
                  0
                  • Higher high and higher low on the daily!
                    0
                • Strong finish! Almost 10% up from todays low at $10.21. Signals further upside $$$
                  0
                  • What is your price predictions about today
                    0
                  • Jobir Avezov Right now it's testing yesterdays closing price. Most important thing today imo is to close above this price - $11.14. If so, I expect further upside. Extremely volatile atm. Impossible to predict but a close above $12 would be super bullish imo.
                    0
                • Price is king, but after reading the clinical results I’m pretty sure this dump is a massive overreaction!
                  0
                  • Do you think it could be up coming weeks?
                    0
                  • Jobir AvezovYes, imo the low is in. My short term target is $14, but could go higher.
                    0
                  • Zman TradingOkay thanks mate
                    0
                • Imo low is in at 10.75. Expecting a rebound.
                  0
                  • Well, almost I guess;-)
                    0
                • I have no idea should I stop loss
                  1
                  • stop loss its exactly what they want from you, to take your loss and buy again.
                    0
                • Time to #BUY !
                  0
                  • WTH happened?
                    0
                    • nothing, no news, just options expiring 😅
                      0
                  • Free fall
                    0
                    • Nearing bottom of bullish channel: time to buy!
                      1
                      • https://www.biospace.com/article/releases/cardiff-oncology-prices-public-offering-sep-30-2020/
                        0
                        • Target 35
                          1
                          • where is this price point heading
                            0
                            • ask nostradamus
                              0
                          • Trovagene and PoC Capital Enter Agreement to Fund Clinical Development of Onvansertib in Metastatic Colorectal Cancer (mCRC) Source: PR Newswire (US) SAN DIEGO, Jan. 29, 2019 /PRNewswire/ -- Trovagene, Inc. (Nasdaq: TROV), a clinical-stage oncology therapeutics company, developing drugs that target cell division (mitosis) for the treatment of leukemias, lymphomas and solid tumor cancers, today announced an agreement with PoC Capital, LLC, to fund clinical development of Onvansertib, Trovagene's first-in-class, 3rdgeneration oral and highly selective Polo-like Kinase 1 (PLK1) inhibitor in a Phase 1b/2 clinical trial in patients with metastatic Colorectal Cancer (mCRC). Trovagene submitted an Investigational New Drug (IND) application and protocol to the FDA on December 19, 2018, and received a "study may proceed" notification from the FDA, 28-days later, on January 16, 2019. The trial will be conducted at two prestigious cancer centers in the U.S.; USC Norris Comprehensive Cancer Cent
                            0
                            • San Diego, CA-based TrovaGene Inc. (NASDAQ:TROV) , a molecular diagnostic company, recently announced encouraging data pertaining to its Precision Cancer Monitoring (PCM) technology for both urine and plasma EGFR mutation testing. Notably, the results demonstrated greater detection sensitivity for PCM compared to tissue testing alone. The data will be presented in Vienna, Austria at the 17th World Conference on Lung Cancer.
                              0
                              • Trovagene to Present Data from Lead Clinical Program of Onvansertib in Acute Myeloid Leukemia at the 60th American Society of...
                                0
                                • news out
                                  0
                                  • Trovagene to Present Data from Lead Clinical Program of Onvansertib in Acute Myeloid Leukemia at the 60th American Society of...Source: PR Newswire (US)SAN DIEGO, Nov. 1, 2018 /PRNewswire/ -- Trovagene, Inc. (NASDAQ: TROV), a clinical-stage oncology therapeutics company, taking a precision medicine approach to develop drugs that target cell division (mitosis) for the treatment of leukemias, lymphomas and solid tumor cancers, today announced that its abstract highlighting data from the Company's lead clinical program in Acute Myeloid Leukemia (AML) has been accepted for presentation at the 60th American Society of Hematology (ASH) Annual Meeting, December 1-4, 2018.The presentation will include data from the ongoing Phase 1b/2 clinical trial of onvansertib (PCM-075), a first-in-class, 3rd generation, highly-selective oral Polo-like Kinase 1 (PLK1) Inhibitor, in combination with standard-of-care low-dose cytarabine (LDAC) or decitabine in patients with relapsed or refractory AML
                                    0